ETF Holdings Breakdown of VNDA

Stock Name	Vanda Pharmaceuticals Inc
Ticker	VNDA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US9216591084
LEI	529900AY8VOOQBKJ0O70

VNDA institutional holdings

The following institutional investment holdings of VNDA have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-11 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 69,114 USD 302,719 -0.9% 4.38

2025-11-11 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 41,127 USD 180,136 -0.9% 4.38

2025-11-11 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 41,127 USD 180,136 -0.9% 4.38

Total = 151,368 USD 662,991
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	69,114	USD 302,719 -0.9%	4.38
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	41,127	USD 180,136 -0.9%	4.38
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	41,127	USD 180,136 -0.9%	4.38
Total =	151,368	USD 662,991

News associated with VNDA

XTX Topco Ltd Has $318,000 Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): XTX Topco Ltd grew its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 378.3% during the first quarter, HoldingsChannel.com reports. The firm owned 69,329 shares of the biopharmaceutical company’s stock after acquiring an additional 54,833 shares during the quarter. XTX Topco Ltd’s holdings in Vanda Pharmaceuticals were worth $318,000 as of […] - 2025-08-11 05:34:58
Vanda (VNDA) Q2 Revenue Rises 4%: Key PointsNet loss (GAAP) widened sharply due to increased spending in Q2 2025, with GAAP EPS was ($0.46) for Q2 2025. - 2025-08-01 05:18:57
GSA Capital Partners LLP Raises Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): GSA Capital Partners LLP increased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 88.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 260,215 shares of the biopharmaceutical company’s stock after acquiring an additional 121,797 shares during the […] - 2025-07-31 04:29:06
Public Employees Retirement System of Ohio Has $426,000 Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Public Employees Retirement System of Ohio reduced its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 16.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 89,032 shares of the biopharmaceutical company’s stock after selling 17,200 shares during the period. Public Employees Retirement System of Ohio […] - 2025-06-05 05:23:00
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Acquired by Two Sigma Advisers LP: Two Sigma Advisers LP raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 156,300 shares of the biopharmaceutical company’s stock after acquiring an additional 15,700 shares […] - 2025-06-03 04:56:54
Short Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expands By 21.4%: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 4,880,000 shares, an increase of 21.4% from the March 31st total of 4,020,000 shares. Based on an average daily volume of 663,100 shares, the days-to-cover ratio is currently 7.4 […] - 2025-05-05 02:35:06
XTX Topco Ltd Makes New Investment in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): XTX Topco Ltd purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 14,496 shares of the biopharmaceutical company’s stock, valued at approximately $69,000. A number of other hedge funds also recently modified their holdings of VNDA. Geode Capital Management LLC boosted […] - 2025-05-01 05:28:58
Geode Capital Management LLC Buys 24,483 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Geode Capital Management LLC raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The fund owned 1,450,310 shares of the biopharmaceutical company’s stock after acquiring an additional 24,483 shares during the period. Geode Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $6,949,000 […] - 2025-04-25 04:26:50
Vanguard Group Inc. Has $16.80 Million Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Vanguard Group Inc. lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 3.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,506,287 shares of the biopharmaceutical company’s stock after selling 125,002 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Vanda Pharmaceuticals worth $16,795,000 as of its most […] - 2025-04-17 04:25:09
ExodusPoint Capital Management LP Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): ExodusPoint Capital Management LP trimmed its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 74.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,506 shares of the biopharmaceutical company’s stock after selling 94,144 shares during the quarter. ExodusPoint […] - 2025-04-15 04:39:18
American Century Companies Inc. Raises Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): American Century Companies Inc. increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 300,276 shares of the biopharmaceutical company’s stock after acquiring an additional 6,079 shares during the […] - 2025-04-10 04:28:52
135,400 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Bought by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 135,400 shares of the biopharmaceutical company’s stock, valued at approximately $649,000. KLP Kapitalforvaltning AS owned […] - 2025-04-02 05:16:59
Bank of New York Mellon Corp Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Bank of New York Mellon Corp lessened its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 14.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 175,017 shares of the biopharmaceutical company’s stock after selling 30,260 shares during the quarter. Bank of New York Mellon Corp’s […] - 2025-03-26 05:12:48
Reviewing Vanda Pharmaceuticals (NASDAQ:VNDA) & Rapport Therapeutics (NASDAQ:RAPP): Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-03-25 03:36:46
Vanda Pharmaceuticals (NASDAQ:VNDA) Given New $20.00 Price Target at HC Wainwright: Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. […] - 2025-02-19 04:56:52
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com: Analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report […] - 2025-02-07 04:20:53
Comparing Vanda Pharmaceuticals (NASDAQ:VNDA) & Cyclerion Therapeutics (NASDAQ:CYCN): Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Profitability This table compares Vanda Pharmaceuticals and […] - 2025-02-05 04:26:43

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.